TransOral Pharmaceuticals (Point Richmond, CA) a specialty pharmaceutical company CNS platform targeting insomnia and alcohol dependence, closed a $40M Series D financing. The deal was led by New Enterprise Associates additional participants included New Leaf Venture Partners, Montreux Equity Partners, InterWest Partners, Hamilton BioVentures, Vivo Ventures and Peninsula Equity Partners.

Tirus Therapeutics (San Diego, CA) a biopharmaceutical company developing next generation antibacterial drugs closed a $20M Series A round. The deal was led by Sofinnova Ventures and joined by InterWest Partners, Prism VentureWorks and Versant Ventures.

PneumRx (Mountain View, CA) a medical device company providing steerable biopsy needle devices to enhance lesion targeting and sampling, raised $27M Series B funding. The round was led by Adams Street Partners and Telegraph Hill Partners additional participants included Sage Venture Partners, Alta Partners, KBL Healthcare Ventures and Spray Venture Partners.

RegImmune (Mountain View, CA) technology platform named reVax is targeting various allergic and immune diseases, with lead indications in allergies and organ rejection has raised a $4.2M Series B round. The deal was lead by NIF SMBC Ventures Co. Ltd. and was joined by Japan Asia Investment Co. Ltd., JAFCO Co. Ltd., Orix Capital Corporation, [...]

Calistoga Pharmaceuticals (Seattle, WA) a drug development startup focused on oncology and inflammation raised a $21M Series A. The deal was led by Frazier Healthcare Ventures and was joined by Alta Partners, Three Arch Partners and Amgen Ventures.

ActoGeniX, (Belgium) is developing a pipeline of therapeutic products based on its TopAct™ technology platform with it’s most advanced candidate for Crohn’s disease, closed a $26M Series A led by GIMV and Life Sciences Partners. New investors include Aescap, Ventech and Baekeland Fonds.

BioBehavioral Diagnostics (Cambridge, MA) a developer of a diagnostic system for measuring the core components of Attention Deficit Hyperactivity Disorder closed a $8.5M Series A financing. The deal was led by Sevin Rosen Funds and Tullis-Dickerson.

AlphaVax (Durham, NC) a developer of vaccine products for infectious diseases (influenza & cytomegalovirus lead), biodefense and cancer, has raised approximately $12.65 million in Series E funding. Investors have not been disclosed.

NextWave Pharma (Buffalo Grove, Ill) a pediatric drug company operating in stealth mode, closed $40M in Series B funding. The round was led by return investors Sofinnova Ventures and Vivo Ventures.

Locus Pharma (Blue Bell, PA) is focused on the development of novel small molecule drug therapies raised a $30.2M Series D financing. The round was led by Novartis Bioventures, Prism Venture Partners and HBM BioVentures. Other participants included S.R. One Capital and L Capital Partners.